CHAIR
:
SPEAKER
(S):
Jason Bernhard, Global Co-Chair, Life Sciences Group, Lazard
Jeff Rona, Chief Business Officer, GlobeImmune Inc.
Timothy Keating, President, Keating Investments
Chris Ehrlich, , Venture Member, InterWest Partners
Description
As your company races to the finish line, be aware that the winner's circle may no longer hold an IPO. Join us for a review of financing vehicles available to mezzanine-stage private companies, the pros and cons of each and a discussion of The Street's perception of alternative strategies for achieving liquidity.
Objectives:
Help CEOs and CFOs examine the pros and cons of various alternative financing vehicles and exit strategies in a slow IPO market.
Provide insights into some of the lesser known financing vehicles such as SPACs, shells and reverse mergers along with the advantages and disadvantages of each.
Help CEOs and CFOs identify who their most interested and likely purchasers could be when an acquisition is a likely scenario.